Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Effectiveness Modelling and Economic Evaluation of Primary HPV Screening for Cervical Cancer Prevention in New Zealand.

Lew JB, Simms K, Smith M, Lewis H, Neal H, Canfell K.

PLoS One. 2016 May 17;11(5):e0151619. doi: 10.1371/journal.pone.0151619. eCollection 2016.

2.

Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.

Apter D, Wheeler CM, Paavonen J, Castellsagué X, Garland SM, Skinner SR, Naud P, Salmerón J, Chow SN, Kitchener HC, Teixeira JC, Jaisamrarn U, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Mindel A, de Sutter P, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group.

Clin Vaccine Immunol. 2015 Apr;22(4):361-73. doi: 10.1128/CVI.00591-14. Epub 2015 Feb 4.

3.

Human papillomavirus testing 2007-2012: co-testing and triage utilization and impact on subsequent clinical management.

Cuzick J, Myers O, Hunt WC, Saslow D, Castle PE, Kinney W, Waxman A, Robertson M, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

Int J Cancer. 2015 Jun 15;136(12):2854-63. doi: 10.1002/ijc.29337. Epub 2014 Dec 1.

4.

Tumour suppressor gene methylation and cervical cell folate concentration are determinants of high-risk human papillomavirus persistence: a nested case control study.

Flatley JE, Sargent A, Kitchener HC, Russell JM, Powers HJ.

BMC Cancer. 2014 Nov 3;14:803. doi: 10.1186/1471-2407-14-803.

5.

Vaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine.

Turner HC, Baussano I, Garnett GP.

PLoS One. 2013 Sep 26;8(9):e75552. doi: 10.1371/journal.pone.0075552. eCollection 2013.

6.

Calibration of complex models through Bayesian evidence synthesis: a demonstration and tutorial.

Jackson CH, Jit M, Sharples LD, De Angelis D.

Med Decis Making. 2015 Feb;35(2):148-61. doi: 10.1177/0272989X13493143. Epub 2013 Jul 25.

7.

The prevalence of human papillomavirus and its impact on cervical dysplasia in Northern Canada.

Jiang Y, Brassard P, Severini A, Mao Y, Li YA, Laroche J, Chatwood S, Corriveau A, Kandola K, Hanley B, Sobol I, Ar-Rushdi M, Johnson G, Lo J, Ratnam S, Wong T, Demers A, Jayaraman G, Totten S, Morrison H.

Infect Agent Cancer. 2013 Jul 1;8(1):25. doi: 10.1186/1750-9378-8-25.

8.

Women's intentions to receive cervical cancer screening with primary human papillomavirus testing.

Ogilvie GS, Smith LW, van Niekerk DJ, Khurshed F, Krajden M, Saraiya M, Goel V, Rimer BK, Greene SB, Hobbs S, Coldman AJ, Franco EL.

Int J Cancer. 2013 Dec 15;133(12):2934-43. doi: 10.1002/ijc.28324. Epub 2013 Jul 16.

9.

Practice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition.

Lee JK, Hong JH, Kang S, Kim DY, Kim BG, Kim SH, Kim YM, Kim JW, Kim JH, Kim TJ, Kim HJ, Kim HS, Ryu HS, Song JY, Ahn HS, Yoo CW, Yoon HK, Lee KH, Lee A, Lee Y, Lee IH, Lee JW, Lee TS, Lim MC, Chang SJ, Chung HH, Ju W, Joo HJ, Hur SY, Hong SR, Nam JH.

J Gynecol Oncol. 2013 Apr;24(2):186-203. doi: 10.3802/jgo.2013.24.2.186. Epub 2013 Apr 5.

10.

The association of HPV-16 seropositivity and natural immunity to reinfection: insights from compartmental models.

Korostil IA, Garland SM, Law MG, Regan DG.

BMC Infect Dis. 2013 Feb 13;13:83. doi: 10.1186/1471-2334-13-83.

11.

HPV-DNA testing for cervical cancer precursors: from evidence to clinical practice.

Origoni M, Cristoforoni P, Costa S, Mariani L, Scirpa P, Lorincz A, Sideri M.

Ecancermedicalscience. 2012;6:258. doi: 10.3332/ecancer.2012.258. Epub 2012 Jun 18.

12.

Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.

Jit M, Chapman R, Hughes O, Choi YH.

BMJ. 2011 Sep 27;343:d5775. doi: 10.1136/bmj.d5775.

13.

HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study.

Kelly RS, Patnick J, Kitchener HC, Moss SM; NHSCSP HPV Special Interest Group.

Br J Cancer. 2011 Sep 27;105(7):983-8. doi: 10.1038/bjc.2011.326. Epub 2011 Sep 6.

14.

Cervical cancer.

Martin-Hirsch PL, Wood NJ.

BMJ Clin Evid. 2011 Jul 27;2011. pii: 0818. Review.

15.

Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England.

Howell-Jones R, Bailey A, Beddows S, Sargent A, de Silva N, Wilson G, Anton J, Nichols T, Soldan K, Kitchener H; Study Group Collaborators.

Br J Cancer. 2010 Jul 13;103(2):209-16. doi: 10.1038/sj.bjc.6605747. Erratum in: Br J Cancer. 2010 Sep 7;103(6):928.

16.

A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial).

Ogilvie GS, van Niekerk DJ, Krajden M, Martin RE, Ehlen TG, Ceballos K, Peacock SJ, Smith LW, Kan L, Cook DA, Mei W, Stuart GC, Franco EL, Coldman AJ.

BMC Cancer. 2010 Mar 24;10:111. doi: 10.1186/1471-2407-10-111.

17.

Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia.

Tropé A, Sjøborg K, Eskild A, Cuschieri K, Eriksen T, Thoresen S, Steinbakk M, Laurak V, Jonassen CM, Westerhagen U, Jacobsen MB, Lie AK.

J Clin Microbiol. 2009 Aug;47(8):2458-64. doi: 10.1128/JCM.01863-08. Epub 2009 Jun 17.

18.

Comparisons of high-risk cervical HPV infections in Caribbean and US populations.

Ragin CC, Watt A, Markovic N, Bunker CH, Edwards RP, Eckstein S, Fletcher H, Garwood D, Gollin SM, Jackson M, Patrick AL, Smikle M, Taioli E, Wheeler VW, Wilson JB, Younger N, McFarlane-Anderson N.

Infect Agent Cancer. 2009 Feb 10;4 Suppl 1:S9. doi: 10.1186/1750-9378-4-S1-S9.

19.

Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study.

Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T; Joint European Cohort Study.

BMJ. 2008 Oct 13;337:a1754. doi: 10.1136/bmj.a1754.

20.

Economic evaluation of human papillomavirus vaccination in the United Kingdom.

Jit M, Choi YH, Edmunds WJ.

BMJ. 2008 Jul 17;337:a769. doi: 10.1136/bmj.a769.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk